CHI Health to use new antibody drug to treat COVID patients

Published: Nov. 18, 2020 at 3:01 PM CST|Updated: Nov. 18, 2020 at 3:23 PM CST
Email this link
Share on Pinterest
Share on LinkedIn

LINCOLN, Neb. (KOLN) - On Friday, November 20, CHI Health will begin infusing qualified, physician-referred patients with Bamlanivimab, an antibody drug that received emergency use authorization from the FDA to help treat COVID-19.

CHI Health received its supply from the federal government, which was then allocated by DHHS. The 14-hospital system has supply for 344 infusions across its Nebraska hospital locations and 39 doses for patients in Iowa. Critical access hospitals will also have access to this supply.

In order to receive a Bamlanivimab infusion, patients will need a positive COVID-19 test, be at a high risk for hospitalization and have a referral from a physician. The patient will then have to consent to the treatment.

In the Metro, CHI Health Midlands will serve as CHI Health’s infusion area and will be open eight hours a day, seven days a week starting on Friday. In Lincoln, Kearney, Council Bluffs, Grand Island and critical access locations, infusion sites will be designated at each hospital location.

Copyright 2020 KOLN. All rights reserved.